We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/10/2018 10:35 | Today's announcement DOES offer some hope for the future. Even if they can't succeed with their own products, they could produce stem cells for others for a wide range of therapies. | dickbush | |
28/9/2018 11:57 | alge - Fine - same as..... jam tomorrow! | deutsch3 | |
27/9/2018 16:40 | Morning Deutsch, I put it in as it appeared not to have been linked at the time. | algernon2 | |
27/9/2018 15:17 | Nice to see the BOD buying shares in the company. | jpuff | |
27/9/2018 09:34 | alge - ?? - The youtube dated 13th Sept is superseded by the RNS on the 19th Sept -is that right? - therefore back to square one? - am I right? - why push the youtube video now partner pulled out and hence no futher £2.5m? | deutsch3 | |
19/9/2018 22:43 | ".. Stifel has a target price of 755p, compared with the current 65p..." | algernon2 | |
19/9/2018 17:19 | Perhaps the 'partner' couldn't raise the additional £2.5m? | deutsch3 | |
19/9/2018 14:09 | Bit of a renexit going on, no deal is better then a bad deal....! Starting to have doubts about that :( | alphapig | |
19/9/2018 13:32 | That would be nice if true fredd1e; here's hoping. | algernon2 | |
19/9/2018 13:20 | Perhaps Reneuron management is after a fair deal and prepared to bargain for it. Not a push over but, in the process, a deal breaker. At least we are 2.5m dollars better off and hopefully other interested parties..... | fredd1eboy | |
19/9/2018 12:10 | "...Importantly, the US company's decision is not related to the hRPC technology itself or to the data generated with the hRPC platform but is instead specific to the US company." Anyone got any idea what this means in practice? It seems to imply there was not an issue with the product or results but some clash maybe with the company's own tech or ideas re progression etc.Any thoughts? | algernon2 | |
19/9/2018 09:07 | Previous news was effectively delays on stroke trial, now this. Very disappointing. | jensonbensonjohnson | |
19/9/2018 08:34 | Commiserations to those who got in on the back of the $5M, 3 month exclusivity news, I very nearly got involved, but fortunately held off. I think these will bounce back (the market cap is more than covered by the cash) it just might be a bit of a wait. | timbo003 | |
19/9/2018 08:22 | scrub that cash call at 60, more like a 40p call coming now! | rocket fuel | |
19/9/2018 08:19 | We get to keep $2.5 million though. | dogwalker | |
19/9/2018 08:02 | Avoid, avoid, avoid. | ken chung | |
19/9/2018 07:25 | Why oh why did I get involved in a company waterloo was in😜...... | nobbygnome | |
19/9/2018 07:17 | RNS: Well, not great news, but we haven't had any of that for some time! | small crow | |
18/9/2018 11:59 | I wonder what the reasoning is behind keeping the name of the US partner quiet? Do you think that's at the request of the partner? I'd like to hear something about the 2nd $2.5M. Should be due any time now. | jensonbensonjohnson | |
17/9/2018 13:00 | BTW, at least some of the 83's are buys. Quiet accumulation. | small crow | |
12/9/2018 09:20 | Stunning results.. Good news in all areas. | bonzo | |
12/9/2018 08:38 | They do imply they don't want to dilute. Of course they might, but unlikely IMO as upfronts likely to come in. | small crow |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions